Barely Significant
← all excerpts

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.

NPJ Breast Cancer · 2021 · PMC8339067 · PMID 34349115

Europe PMCDOI
1
hedged sentence
0.1100
closest p · 2.2× alpha
0.1100
boldest claim

The sentences

a significant trendP = 0.11not close (p > 0.1)
The C max was significantly correlated with the dose ( r = 0.606, P = 0.037) although AUC 24 did not exhibit a significant trend toward increasing values as the dose was escalated from 300 to 600 mg ( r = 0.486, P = 0.11).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.